Goldman Sachs’s Audentes Therapeutics, Inc BOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-790,053
| Closed | -$47.3M | – | 5753 |
|
|
2019
Q4 | $47.3M | Buy |
790,053
+326,201
| +70% | +$12.2M | 0.01% | 1188 |
|
|
2019
Q3 | $13M | Buy |
463,852
+126,156
| +37% | +$4.31M | ﹤0.01% | 2136 |
|
|
2019
Q2 | $12.8M | Buy |
337,696
+80,561
| +31% | +$3.1M | ﹤0.01% | 2194 |
|
|
2019
Q1 | $10M | Buy |
257,135
+106,578
| +71% | +$3.06M | ﹤0.01% | 2414 |
|
|
2018
Q4 | $3.21M | Sell |
150,557
-46,213
| -23% | -$1.19M | ﹤0.01% | 3231 |
|
|
2018
Q3 | $7.79M | Buy |
196,770
+21,328
| +12% | +$795K | ﹤0.01% | 2635 |
|
|
2018
Q2 | $6.7M | Buy |
175,442
+133,213
| +315% | +$4.93M | ﹤0.01% | 2744 |
|
|
2018
Q1 | $1.27M | Sell |
42,229
-37,868
| -47% | -$1.28M | ﹤0.01% | 3903 |
|
|
2017
Q4 | $2.5M | Buy |
80,097
+65,092
| +434% | +$1.79M | ﹤0.01% | 3596 |
|
|
2017
Q3 | $420K | Buy |
15,005
+86
| +0.6% | +$1.87K | ﹤0.01% | 5220 |
|
|
2017
Q2 | $285K | Sell |
14,919
-3,472
| -19% | -$55.5K | ﹤0.01% | 5549 |
|
|
2017
Q1 | $313K | Sell |
18,391
-312
| -2% | -$5.05K | ﹤0.01% | 5435 |
|
|
2016
Q4 | $342K | Buy |
18,703
+6,099
| +48% | +$105K | ﹤0.01% | 5378 |
|
|
2016
Q3 | $224K | Buy |
+12,604
| New | +$191K | ﹤0.01% | 5735 |
|
Goldman Sachs's BOLD Position: Q1 2020 in Review
Goldman Sachs sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 790,053 shares — an estimated $47.3M sold.
Goldman Sachs first reported a position in BOLD in Q3 2016 and held it in 14 quarters. The position peaked at $47.3M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.
- Goldman Sachs reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
- Goldman Sachs sold 790,053 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $47.3M.
- Goldman Sachs first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 14 quarters.
- Goldman Sachs's Audentes Therapeutics, Inc position peaked at $47.3M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.
Based on Goldman Sachs's 13F filing for Q1 2020, filed 15 May 2020.